Survey Assessment of Continuation of and Satisfaction with Pharmacological Treatment for Urinary Incontinence  by Campbell, Ulka B. et al.
Survey Assessment of Continuation of and Satisfaction with
Pharmacological Treatment for Urinary Incontinence
Ulka B. Campbell, PhD,1 Paul Stang, PhD,1 Rich Barron, MS2
1Cerner Galt, New York, NY, USA; 2Allergan Corp, Inc. Irvine, CA, USA
ABSTRACT
Purpose: To evaluate treatment satisfaction and compliance
with pharmacologic therapy in urinary incontinence patients.
Materials and Methods: An online survey was returned by
1447 individuals from a nationwide panel of adults who had
previously reported treatment for incontinence symptoms
and agreed to participate in survey research. Data on demo-
graphics, incontinence severity, treatment compliance, and
satisfaction were obtained. Logistic regression was used to
estimate crude and adjusted odds ratios (ORs) and 95%
conﬁdence intervals (CIs) for characteristics associated with
pharmacologic treatment dissatisfaction and discontinuation.
Results: The sample was predominantly female (87%) and
white (93%) with a mean age of 56 years. On average,
patients urinated 10 times/day and experienced 16 wetting
accidents in the week preceding survey. Overall, 25%
reported being somewhat or very dissatisﬁed with treatment.
Those who reported a severe effect of incontinence on their
lives were most likely to be dissatisﬁed (OR = 2.82, 95%
CI = 1.89–4.23). Discontinuation of drug treatment was
reported by 45% of study subjects, with major reasons being
poor efﬁcacy (in 41.3% of discontinuations), side effects
(22.4%), and cost (18.7%). Predictors for discontinuation
included young age (OR = 1.8, 95% CI = 1.2–2.8), experi-
encing symptoms for 10 or more years (OR = 1.5, 95%
CI = 1.1–2.0), and experiencing more than 16 wetting acci-
dents in the last week (OR = 1.6, 95% CI = 1.3–2.1).
Conclusions: This online survey of self-selected incontinence
patients indicated that almost half of those who have received
drug treatment for incontinence had discontinued primarily
because of lack of efﬁcacy, side effects, and cost concerns.
Our ﬁndings suggest a substantial degree of unmet need from
current therapy among those with incontinence.
Keywords: compliance, drug therapy, survey, treatment
efﬁcacy, urinary incontinence.
Introduction
Urinary incontinence is a disabling condition that
afﬂicts approximately 13 million individuals in the
United States [1]; worldwide prevalence estimates vary
from 10 to 50% [2] depending on the age, sex, and
disease deﬁnition criteria applied [3,4]. The associated
economic costs of incontinence are substantial, with
recent total estimates reaching US$12 billion [5]. More
than 97% are direct costs [6] made up of diagnostic
tests, doctor visits, surgery, protective measures (e.g.,
pads), institutionalization, and nonpharmacological
and pharmacological therapy. Nonpharmacological
treatments include pelvic muscle rehabilitation,
bladder training/timed voiding, electrical stimulation,
and surgical interventions [3,7,8]. First-line pharmaco-
therapy for urge incontinence consists of anticholin-
ergics, including tolterodine (Detrol, Detrol LA) and
oxybutynin (Ditropan, Ditropan XL) [3,7,8]. Stress
incontinence may be pharmacologically treated with
estrogen therapy and/or alpha-adrenergic agonists [9].
For both types of incontinence, drug therapies appear
to be especially effective when combined with behav-
ioral intervention [10].
Despite available therapies, relatively few individu-
als suffering from incontinence seek health care
[11–13] and, of those who do, few are compliant or
persist with therapy [14–16]. For example, persistence
rates with oxybutynin or tolterodine were 32–44% at
1 month, 22% at 6 months, and dropped to 5–11%
at 12 months in two Medicaid populations [14,16].
Compliance rates, as reported for one of these popu-
lations, were even more alarming—less than 5% of
patients were compliant at 6 months and 0.7% were
adherent at 12 months [16]. As both compliance and
persistence are crucial to treatment success, it is impor-
tant to discover why these rates are so low. Analysis of
demographic characteristics determined that patients
were more likely to persist with therapy if they were
young (<18 years old) or middle-aged (40–64 years),
white, or their incontinence was recently diagnosed.
Patients with a history of depression or urinary tract
infection, or who were taking multiple drugs (for any
condition) were less likely to persist with treatment.
The roles of pharmacotherapy and any associated
adverse events are uncertain. In one study oxybutynin
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favorably affected persistence over tolterodine [16],
whereas in two others oxybutynin was associated with
a signiﬁcantly higher risk of treatment discontinuation
than was tolterodine [14,17].
Although prescription database analyses provide
useful quantitative information about persistence with
therapy, they do not provide any qualitative insight
into the reasons why patients discontinue their incon-
tinence medication [14–19]. Given the costs related to
burden of illness and the impact of urinary inconti-
nence on quality of life and mental well being, patient
dissatisfaction and discontinuation of treatment
have substantial personal and economic ramiﬁcations
[20,21], and further examination of these variables is
warranted. The aim of this study was to investigate
types of treatments (pharmaceutical or surgical) used
by patients with urinary incontinence, their satisfac-
tion with treatment, and the rate of and reasons
for discontinuation of pharmacological treatment. We
hoped that our qualitative assessment of reasons for
incontinence treatment discontinuation would gener-
ate hypotheses for further research.
Methods
In collaboration with National Family Opinion (NFO)
World Group, we screened an online nationwide data-
base of 100,000 adults (at least 18 years of age) who
have agreed to participate in survey research. From
this group, which is representative of the US popula-
tion and potentially includes any type of medical insur-
ance coverage, we invited individuals to participate in
the survey if they met the following criteria: 1) aged 18
or more years; 2) previously reported receiving pre-
scription or over-the-counter (OTC) medications for
treatment of incontinence symptoms (number of pre-
scription ﬁlls not speciﬁed); and 3) not participating in
another survey. Informed consent was implicit in the
voluntary nature of the survey process.
The initial part of the survey consisted of four ques-
tions, including sex, age, duration of incontinence
symptoms and timing of treatment. The remainder of
the survey, which was developed speciﬁcally for this
analysis, consisted of 29 questions related to inconti-
nence (type, duration and frequency of symptoms, and
overall impact of incontinence on life) and to inconti-
nence treatment (use and type of treatment within last
4 weeks, efﬁcacy in alleviating symptoms and improv-
ing ability to perform activities of daily living, impact
of treatment of quality of life parameters [mood, rela-
tionships], discontinuation of treatment, which treat-
ments were discontinued, occurrence and severity of
any side-effects, and satisfaction). To assess impact of
incontinence symptoms, patients were asked “what is
the overall impact of incontinence on your life?”, and
given the options of “no effect,” “mild effect,” “mod-
erate effect” or “severe effect.” Satisfaction with treat-
ment was evaluated on a 5-point Likert scale from
“very satisﬁed” to “very dissatisﬁed.” Development
and evaluation of the Patient Satisfaction with Treat-
ment scale used in this study has been described pre-
viously [22,23]. The reliability and validity of the
questionnaire was demonstrated in a group of incon-
tinence patients (n = 891) similar to ours on the basis
of age, sex, educational background, duration of
symptoms, and mean urination and incontinence fre-
quency [23]. Information on demographic variables,
including ethnicity, education attainment, household
income and geographic region of residence, were
obtained from an initial recruitment survey sent to
potential panel members.
We performed descriptive analyses, calculating the
means and frequency distributions of the survey vari-
ables. To examine predictors of overall satisfaction
with treatment, we compared two categories: very
dissatisﬁed/somewhat dissatisﬁed versus very satisﬁed/
somewhat satisﬁed. Frequency of urination and
wetting accidents were dichotomized according to the
median of each distribution (10 vs. >10 urinations
per day and 16 vs. >16 wetting accidents per week).
For each of these outcomes, logistic regression was
used to estimate both unadjusted (i.e., crude) and
adjusted odds ratios (ORs) for age, duration of incon-
tinence symptoms, and severity of incontinence (mea-
sured as impact on life, urination frequency and
wetting accident frequency). For each predictor vari-
able, we adjusted for the other variables to examine
the impact of potential confounders on the association
with the outcome. Ninety-ﬁve percent conﬁdence inter-
vals (CIs) were calculated to describe the precision of
the effect estimates obtained from the regression
models. Statistical signiﬁcance was indicated by the
95%CI not including 1.0.
Results
Overall, 3193 individuals were eligible for survey par-
ticipation and 1447 individuals returned a completed
survey, and made up the study sample in this analysis.
The demographic characteristics of the study sample
are summarized in Table 1. The mean age of the study
sample was 56 years; approximately a third was
between the ages of 50 and 59 years. The vast majority
of study participants were female (87%) and white
(93%). More than half had less than a college educa-
tion, a household income of less than $60,000 and
resided in the mid-western or southern United States.
Table 2 describes the overall distribution of dura-
tion and severity of incontinence symptoms. Very few
subjects were afﬂicted for less than a year (1.6%) or
reported no effect of incontinence on life (2.5%). On
average, subjects reported urinating approximately 10
times a day and experiencing nearly 16 wetting acci-
dents during the week prior to survey. Eighty-one
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percent experienced wetting accidents while laughing,
sneezing, coughing, or exercising indicating some
degree of stress incontinence.
Sixty-three percent of individuals had received
pharmacological or surgical treatment for urinary
incontinence within the last month; 30% received
pharmacological or surgical treatment more than
6 months ago (Table 3). The most common prescrip-
tion treatment was Detrol LA (27%). Less commonly
used pharmacotherapies included Ditropan XL (18%),
and Ditropan (14%). Use of drugs administered or
injected directly into the bladder was extremely rare
(1% for each treatment type). When asked to rate
overall satisfaction with incontinence treatment, 25%
reported being somewhat dissatisﬁed or very dissatis-
ﬁed (Table 4). Forty-ﬁve percent of patients (n = 651)
reported a reason for discontinuing drug treatment,
the most frequent being a lack of treatment efﬁcacy
Table 1 Demographic characteristics of study sample
Demographic characteristic n (%)
Age (years)*
18–39 139 (9.6)
40–49 287 (19.8)
50–59 479 (33.1)
60–69 305 (21.1)
70 or more 237 (16.4)
Sex
Male 195 (13.5)
Female 1252 (86.5)
Race†
White 1349 (93.2)
Black/African-American 40 (2.8)
Asian/Paciﬁc Islander 7 (0.5)
Native American 20 (1.4)
Other 17 (1.2)
Unknown 14 (1.0)
Education
High school or less 327 (22.6)
Some college—no degree 540 (37.3)
Associate’s degree 160 (11.1)
Bachelor’s degree 281 (19.4)
Postgraduate degree 132 (9.1)
Unknown 7 (0.5)
Household income
Less than $22,500 290 (20.0)
$22,500–39,999 389 (26.9)
$40,000–59,999 350 (24.2)
$60,000–89,999 247 (17.1)
$90,000 or more 171 (11.8)
Geographic region
Northeast 257 (17.8)
Midwest 410 (28.3)
South 499 (34.5)
West 281 (19.4)
Total 1447 (100.0)
*The mean age of the study sample was 56.3 years (standard deviation 13.5).
†1.8% of the study sample reported being of Spanish origin (n = 26).
Table 2 Duration and severity of urinary incontinence
symptoms (n = 1447)
n (%)
Duration of symptoms (years)
Less than 1 23 (1.6)
1 to <3 308 (21.3)
3 to <6 443 (30.6)
6 to <10 330 (22.8)
>10 343 (23.7)
Effect of incontinence on life
No effect 36 (2.5)
Mild effect 493 (34.1)
Moderate effect 658 (45.5)
Severe effect 260 (18.0)
Experience wetting accidents while laughing,
sneezing, coughing, or physical exercise
Yes 1174 (81.1)
No 273 (18.9)
Number of times of urination per day*
0–4 86 (5.9)
5–7 306 (21.2)
8–10 611 (42.2)
11–15 331 (22.9)
16+ 113 (7.8)
Number of wetting accidents in last week†
0 117 (8.1)
1–7 663 (45.8)
8–14 238 (16.5)
15+ 429 (29.7)
*Mean 10.3, standard deviation 6.6.
†Mean 15.9, standard deviation 22.0.
Table 3 Use of treatment for urinary incontinence symptoms
(n = 1447)
n (%)
Timing of treatment
Within the last 1 month 907 (62.7)
1 month to <3 months ago 45 (3.1)
3 months to <6 months ago 66 (4.6)
6 months ago 429 (29.7)
Use of prescription treatments in the past 4 weeks*
Detrol 122 (8.4)
Detrol LA 397 (27.4)
Ditropan 207 (14.3)
Ditropan XL 258 (17.8)
Other oral medication 147 (10.2)
Oxytrol (topical patch) 49 (3.4)
Drug administered directly into bladder 11 (0.8)
Drug injections into bladder 10 (0.7)
None of the above 98 (6.8)
Have not used a prescription treatment
in the past 4 weeks
293 (20.3)
Undergone surgery for incontinence in past 4 weeks 93 (6.4)
*Because categories are not mutually exclusive, proportions do not sum to 100%.
Table 4 Satisfaction with treatment and reasons for discon-
tinuing drug treatment for incontinence symptoms (n = 1447)
n (%)
Overall satisfaction with treatment
Very satisﬁed 273 (18.9)
Somewhat satisﬁed 475 (32.8)
Neutral 336 (23.2)
Somewhat dissatisﬁed 208 (14.4)
Very dissatisﬁed 155 (10.7)
Reason for discontinuing drug treatment 651 (45.0)
Cost of treatment* 122 (18.7)
Side effects of treatment* 146 (22.4)
No need for frequent use of treatment* 56 (8.6)
No insurance coverage for treatment* 75 (11.5)
Medication did not work well* 269 (41.3)
Other* 180 (27.7)
Have not discontinued treatment 796 (55.0)
*Denominator of proportion consists of subjects who reported a reason for discon-
tinuing treatment (n = 651). Because categories are not mutually exclusive, propor-
tions do not sum to 100%.
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(41%). Less commonly reported reasons included side-
effects (22%), cost (19%) and other unspeciﬁed
reasons (28%).
Table 5 presents the crude and adjusted ORs (and
95% CIs), respectively, for the associations between
age and disease severity measures and the outcome of
treatment dissatisfaction. Age was not signiﬁcantly
associated with treatment dissatisfaction; nevertheless,
there was a nonsigniﬁcant trend for subjects aged
18–39 years to be less satisﬁed with treatment com-
pared with those aged 70 or more years (crude
OR = 0.61; 95% CI 0.37–1.03). This association
diminished with increasing age. The trend became
slightly diminished on adjustment for duration of symp-
toms, effect of incontinence on life, urination frequency
andwetting accident frequency. After adjustment, dura-
tion of symptoms appeared to have no impact on
treatment dissatisfaction (OR ranged from 1.05 to
1.15), and patients with symptoms for 3 or more years
had similar levels of dissatisfaction as those with symp-
toms less than 3 years. Compared with subjects who
reported no effect or a mild effect of incontinence on
their lives, subjects who reported amoderate effect were
more likely to report dissatisfaction with treatment
(OR = 2.61; 95%CI 1.90–3.58), whereas those who
reported a severe effect were even more likely to be
dissatisﬁed with treatment (OR = 4.21; 95% CI 2.89–
6.14). Although these associations became attenuated
after controlling for the other variables, the signiﬁcant
association persisted. The results for other measures of
disease severity (i.e., urination frequency and wetting
accident frequency) were consistent with these results.
After adjustment, subjects who urinated more than 10
times a day and subjects who reported more than 16
wetting accidents in the past week were signiﬁcantly
more likely to be dissatisﬁed with treatment
(OR = 1.81, 95%CI 1.36–2.40 and OR = 2.24, 95%
CI 1.67–3.00, respectively).
Finally, we explored predictors of treatment discon-
tinuation. Table 6 presents the crude and adjusted ORs
(95% CI) for the associations between age and disease
severity measures and discontinuation. As in the pre-
vious logistic regression models of dissatisfaction,
frequency of urination and wetting accidents were
dichotomized according to the median of each distri-
bution (10 vs. >10 urinations and 16 vs. >16
wetting accidents). Compared with subjects 70 years
and older, subjects 18–39 years and subjects
40–49 years were signiﬁcantly more likely to discon-
tinue treatment (crude OR = 1.76; 95% CI 1.15–2.68
and crude OR = 2.12, 95% CI 1.49–3.01, respec-
tively). In contrast, no signiﬁcant association between
age and treatment discontinuation was observed for
subjects 50–59 years or 60–69 years. Adjustment for
Table 5 Unadjusted and adjusted odds ratios and 95% conﬁ-
dence intervals obtained from logistic regression models for the
associations between overall dissatisfaction with treatment* and
age,duration of symptoms,effect of incontinence on life, urination
frequency, and wetting accident frequency (N = 1111)
Unadjusted OR
(95% CI)
Adjusted OR†
(95% CI)
Age (years)
18–39 0.61 (0.37–1.03) 0.67 (0.38–1.15)
40–49 0.66 (0.43–1.00) 0.64 (0.41–1.00)
50–59 0.73 (0.50–1.06) 0.73 (0.49–1.09)
60–69 0.89 (0.60–1.34) 0.90 (0.59–1.39)
70+ 1.00 (referent) 1.00 (referent)
Duration of symptoms
(years)
Less than 3 1.00 (referent) 1.00 (referent)
3 to <6 1.19 (0.83–1.69) 1.05 (0.72–1.53)
6 to <10 1.42 (0.98–2.06) 1.15 (0.77–1.71)
>10 1.45 (1.00–2.10) 1.07 (0.72–1.60)
Effect of incontinence on life
No or mild effect 1.00 (referent) 1.00 (referent)
Moderate effect 2.61 (1.90–3.58) 2.07 (1.49–2.89)
Severe effect 4.21 (2.89–6.14) 2.82 (1.89–4.23)
Urination frequency (times/
day)
10 1.00 (referent) 1.00 (referent)
>10 2.38 (1.83–3.11) 1.81 (1.36–2.40)
Wetting accident frequency
(times/week)
16 1.00 (referent) 1.00 (referent)
>16 3.14 (2.38–4.15) 2.24 (1.67–3.00)
*Outcome was deﬁned as dissatisfaction with treatment (answer of very or some-
what dissatisﬁed or neutral to the question about overall satisfaction with treatment)
versus satisfaction (answer of very or somewhat satisﬁed).
†Odds ratios were adjusted for all other variables listed in the table.
CI, conﬁdence interval, OR, odds ratio.
Table 6 Unadjusted and adjusted odds ratios and 95% conﬁ-
dence intervals obtained from logistic regression models for the
associations between discontinuation of treatment* and age,
duration of symptoms, effect of incontinence on life, urination
frequency and wetting accident frequency (N = 1447)
Unadjusted OR
(95% CI)
Adjusted OR†
(95% CI)
Age (years)
18–39 1.76 (1.15–2.68) 1.82 (1.18–2.80)
40–49 2.12 (1.49–3.01) 2.15 (1.50–3.07)
50–59 1.33 (0.97–1.83) 1.35 (0.98–1.87)
60–69 0.95 (0.67–1.35) 0.93 (0.65–1.33)
70+ 1.00 (referent) 1.00 (referent)
Duration of symptoms
(years)
<3 1.00 (referent) 1.00 (referent)
3 to <6 1.22 (0.91–1.63) 1.27 (0.95–1.71)
6 to <10 1.53 (1.12–2.08) 1.56 (1.13–2.14)
>10 1.45 (1.07–1.97) 1.46 (1.07–2.01)
Effect of incontinence on life
No or mild effect 1.00 (referent) 1.00 (referent)
Moderate effect 0.85 (0.68–1.07) 0.73 (0.57–0.93)
Severe effect 0.90 (0.67–1.21) 0.68 (0.49–0.94)
Urination frequency (times/
day)
10 1.00 (referent) 1.00 (referent)
>10 1.22 (0.98–1.53) 1.17 (0.92–1.48)
Wetting accident frequency
(times/day)
16 1.00 (referent) 1.00 (referent)
>16 1.50 (1.18–1.89) 1.64 (1.27–2.11)
*Outcome was deﬁned as discontinued treatment (n = 651) versus did not discon-
tinue treatment (n = 796).
†Odds ratios were adjusted for all other variables listed in the table.
CI, conﬁdence interval; OR, odds ratio.
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duration of symptoms, effect of incontinence on life,
urination frequency and wetting accident frequency
did not materially affect the magnitude of these asso-
ciations. Duration of symptoms was weakly associated
with treatment discontinuation. Compared with sub-
jects who had experienced symptoms for less than
3 years, the OR for discontinuation in subjects with
symptoms for 3 years to less than 6 years was not
signiﬁcant (crude OR 1.22; 95% CI 0.91–1.63). Nev-
ertheless, the OR was signiﬁcant in those with dura-
tion of symptoms 6 or more years (OR of 1.45 and
1.53; 95% CI did not include 1.0). After adjustment,
those who reported a moderate or severe effect of
incontinence were less likely to discontinue treatment
(OR = 0.73; 95% CI 0.57–0.93). Although daily uri-
nation frequency was not associated with treatment
discontinuation (adjusted OR = 1.17; 95% CI 0.92–
1.48), subjects who experienced more than 16 wetting
accidents in the last week were more likely to discon-
tinue treatment than subjects who experienced up to
16 wetting accidents (adjusted OR = 1.64; 95% CI
1.27–2.11).
Discussion
We conducted an online survey of adults suffering from
incontinence to assess the impact of patient and disease
characteristics on satisfaction and persistence with
treatment. Our ﬁndings suggest that patient dissatisfac-
tion with treatment is strongly associated with disease
severity, which we assessed in several different ways
(impact of incontinence on life, urination frequency and
wetting accident frequency). Because this was a cross-
sectional study, it is difﬁcult to establish the temporal
relationship between disease severity and satisfaction
with treatment; i.e., whether severe disease leads to lack
of efﬁcacy (and thus dissatisfaction) or whether lack of
efﬁcacy leads to experience of symptoms. Because our
deﬁnition of severity could have reﬂected treatment
failure, our study sample may not accurately represent
the spectrum of disease in the general population of
incontinence patients. Despite this limitation, these
results indicate potential inadequacies in the efﬁcacy of
frequently used pharmacotherapies.
Indeed, the most commonly cited reason for discon-
tinuing treatment was lack of efﬁcacy. Although less
common, side-effects and costs associated with treat-
ment were also responsible for discontinuation. The
overall rate of persistence in our study was 55%. Of
the 796 subjects who reported not discontinuing treat-
ment, 682 (85.7%) reported that they were currently
receiving treatment or had received treatment in the
last four weeks. Our persistence rate is markedly
higher than in other studies which have reported per-
sistence rates of around 10–20% over a 6- to
12-month period [14,16]. These studies did not ques-
tion patients about why they discontinued their medi-
cation and thus are difﬁcult to compare with our study,
but it is interesting that both found that the type of
treatment used had a signiﬁcant impact (adverse or
otherwise) on persistence levels [14,16]. We found that
patients who reported a severe effect of incontinence
on their lives were more likely to be dissatisﬁed with
treatment but less likely to discontinue treatment than
patients who reported no effect or a mild effect of
incontinence. On the other hand, a high number of
wetting accidents per week was signiﬁcantly associated
with both treatment dissatisfaction and treatment dis-
continuation. Urination frequency was signiﬁcantly
associated with treatment dissatisfaction but not with
discontinuation. One explanation is that, although
treatments are not ideally efﬁcacious, some symptom
relief is better than none, implying a substantial
burden of incontinence symptoms on the lives of
patients. This is consistent with past research demon-
strating that urinary incontinence symptoms can
severely diminish quality of life [20,21,24].
Withdrawal rates for incontinence treatments in the
clinical trial setting are around 10–15% over 12 weeks
[25–27], rising to 30–40% when the studies continue
for 9–12 months [28,29]. An analysis of prescription
of overactive bladder or incontinence pharmacothera-
pies showed that the discontinuation rate was much
higher during routine clinical practice—67% at
90 days, and 78% at 6 months [16]. These latter
ﬁgures are more compatible with the current survey
withdrawal rate of 45% than are the clinical trial data.
In addition, although the clinical trial data cite adverse
events as the most common reason for treatment dis-
continuation, we found that patients mostly ceased
therapy because of a lack of drug effects. This probably
reﬂects the artiﬁcial nature of the clinical trial setting
where high levels of patient education, contact and
follow-up can inﬂuence patient compliance and persis-
tence. Patients may be more inclined to persist with a
relatively ineffective therapy in a clinical trial setting
than in clinical practice. Researchers have shown that
implementing health education intervention programs
for overactive bladder within the community can
favorably inﬂuence patient compliance, but not signiﬁ-
cantly [30]. These ﬁndings highlight the difﬁculty of
inﬂuencing patient compliance or adherence in the face
of poor drug efﬁcacy or tolerability.
Another potential reason for the lower discontinu-
ation rates in clinical trials is careful patient selection.
Our survey population included a high proportion of
patients with symptoms of stress urinary incontinence,
a condition which is relatively resistant to phar-
macotherapy. Therefore, the high discontinuation
rate for lack of efﬁcacy seen in our study may have
been a consequence of poor treatment choice by the
patient’s physician. In contrast, in a clinical trial,
patients are carefully selected as suitable candidates
for pharmacotherapy.
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This survey was undertaken using a volunteer, self-
selected sample of subjects with incontinence. As such,
we are unable to accurately determine the extent to
which they, and the features of their disease, are rep-
resentative of the spectrum of incontinence and its
sufferers. In addition, we did not compare the features
of patients who returned the completed questionnaire
with those who met the inclusion criteria but did not
complete the survey. Nevertheless, it is still worth
noting some of the similarities between the demo-
graphic characteristics of our patient sample and those
of other epidemiological surveys of incontinence popu-
lations. No single study has ever determined the preva-
lence of urinary incontinence (as a general term) across
the whole US population. The most comprehensive
epidemiological survey to date is the National Overac-
tive BLadder Evaluation (NOBLE) Program which
investigated the prevalence of overactive bladder with
and without urge incontinence in more than 5000
adults representative of the US population [21].
According to this survey, the prevalence of urgency-
related bladder control problems is similar in men and
women, but women suffer from incontinence more
often than men. This may explain why the vast major-
ity of our subjects were female and why other studies
of incontinence prevalence have also found that
women are over-represented in comparison to men
[11,31]. Compared with NOBLE, our study contained
lower percentages of Black or Hispanic subjects,
although education levels were similarly represented.
Age and household income comparability could not be
determined because of the different ranges used.
It is important to keep inmind that survey research is
particularly susceptible to response bias wherein those
with a particular interest or motivation to respond may
be over-represented in the ﬁnal sample. If this is more
likely among those who are not currently satisﬁed with
their therapy or suffer a disproportionate impact of the
illness on their life, then our results may overstate these
features in the population. The online nature of the
survey may also bias the results, because it can only be
taken by individuals who have access and are capable of
using the internet. Thus, the number of elderly subjects
and/or those of low household income in our study
may not sufﬁciently represent incontinence sufferers in
these general subpopulations. Men are also under-
represented relative to the NOBLE population [21].
Care must be exercised in generalizing the results of this
study beyond populations with similar characteristics.
Similarly, our survey was limited to patients who
were currently taking pharmacological treatment or
had received any treatment within the previous
4 weeks. Therefore, although we asked about discon-
tinuation of any drug treatment at any time in the past,
the survey was biased towards patients currently or
recently receiving treatment. This may underestimate
the long-term discontinuation rates with drug therapy
by being biased towards: 1) patients who are newly
treated and not yet discontinued; and 2) patients
who are more motivated towards trying treatment
again, despite a previous discontinuation. In addition,
although our survey questions asked speciﬁcally about
symptoms of stress incontinence (the frequency of
“wetting accidents” associated with sneezing or exer-
cise), we did not ask speciﬁcally about urinary urge
incontinence (i.e., involuntary urine leakage accompa-
nied or immediately preceded by urgency). This poten-
tially biases our results towards a population with
predominantly stress incontinence compared with
other forms of incontinence or overactive bladder.
Finally, our question about pharmacologic therapies
was speciﬁc to prescription medication, and we did not
question our survey respondents on their use of OTC
medications. This was based on the fact that we were
not aware of any OTC medications for incontinence at
the time of the survey. Nevertheless, we cannot rule out
the possibility that a proportion of 10.2% of patients
who reported using “other oral agents” were taking an
OTC agent.
To the best of our knowledge, this is only the second
online survey used to assess incontinence in the United
States. The ﬁrst online interviews were conducted in
2004 and sought to understand how people managed
incontinence [12]. Using very open criteria, the survey
found that 32% of Americans between the age of 30
and 70 years had experienced loss of bladder control
at least once in their lives, but only 13% of those with
symptoms had ever been formally diagnosed and most
(64%) were not using any form of treatment or
product to manage their incontinence. As with our
survey, women were far more likely than men to have
symptoms.
In summary, lack of efﬁcacy was the most common
self-reported reason for discontinuing pharmacological
treatment in this online self-selected sample of inconti-
nence patients, predominantly women, and on multi-
variate analysis, the frequency of wetting accidents
was associated with lack of persistence. Thus, our
results indicate a substantial degree of unmet need from
current therapy among those with incontinence. Other
surveys have shown that women with urinary inconti-
nence expect at least a 70% reduction in incontinence
episodes to consider a treatment effective [32], and that
there can be quite a discrepancy between patients’ and
doctors’ perception of the “bother” caused by inconti-
nence symptoms [33]. All these ﬁndings have consider-
able clinical implications with regard to adequately
meeting patients’ needs, and help to explain the poor
persistence rates with incontinence therapy seen in pre-
scription database analyses [14,16]. To more fully
understand the reasons for lack of persistence with
pharmacotherapy, future studies should focus on the
links between efﬁcacy, side-effects, quality of life, and
treatment discontinuation in nontrial settings.
Compliance survey of OAB Treatment 731
Source of ﬁnancial support: This study was supported by a
research grant from Allergan, Inc.
References
1 National Institute of Diabetes and Digestive and
Kidney Diseases. National Kidney and Urologic
Diseases Information Clearinghouse. Available from:
http://kidney.niddk.nih.gov/kudiseases/pubs/uiwomen
[Accessed April 30, 2005].
2 Getsios D, El-Hadi W, Caro I, et al. Pharmacological
management of overactive bladder: a systematic and
critical review of published economic evaluations.
Pharmacoeconomics 2005;23:995–1006.
3 Fantl J, Newman DK, Colling J, et al. Urinary Incon-
tinence in Adults: Acute And Chronic Management.
Rockville, MD: US Department of Health and Human
Services, Public Health Service, AHCPR publication
96-0682. Clinical Practice Guideline No. 2, 1996
update; 1996 March.
4 Thom D. Variation in estimates of urinary inconti-
nence prevalence in the community: effects of differ-
ences in deﬁnition, population characteristics, and
study type. J Am Geriatr Soc 1998;46:473–80.
5 Hu TW, Wagner TH, Bentkover JD, et al. Estimated
economic costs of overactive bladder in the United
States. Urology 2003;61:1123–8.
6 Wagner TH, Hu TW. Economic costs of urinary
incontinence in 1995. Urology 1998;51:355–61.
7 Jabs CF, Stanton SL. Urge incontinence and detrusor
instability. Int Urogynecol J Pelvic Floor Dysfunct
2001;12:58–68.
8 Kim HL, Gerber GS, Patel RV, et al. Practice patterns
in the treatment of female urinary incontinence: a
postal and internet survey. Urology 2001;57:45–8.
9 Mold JW. Pharmacotherapy of urinary incontinence.
Am Fam Physician 1996;54:673–80,683–5.
10 Mattiasson A, Blaakaer J, Hoye K, et al. Simpliﬁed
bladder training augments the effectiveness of toltero-
dine in patients with an overactive bladder. BJU Int
2003;91:54–60.
11 Lagace EA, Hansen W, Hickner JM. Prevalence and
severity of urinary incontinence in ambulatory adults:
an UPRNet study. J Fam Pract 1993;36:610–14.
12 Muller N. What Americans understand and how they
are affected by bladder control problems: highlights
of recent nationwide consumer research. Urol Nurs
2005;25:109–15.
13 Roberts RO, Jacobsen SJ, Rhodes T, et al. Urinary
incontinence in a community-based cohort: preva-
lence and healthcare-seeking. J Am Geriatr Soc 1998;
46:467–72.
14 Shaya FT, Blume S, Gu A, et al. Persistence with over-
active bladder pharmacotherapy in a Medicaid popu-
lation. Am J Manag Care 2005;11(Suppl.):S121–9.
15 Visco AG, Weidner AC, Cundiff GW, et al. Observed
patient compliance with a structured outpatient
bladder retraining program. Am J Obstet Gynecol
1999;181:1392–4.
16 Yu YF, Nichol MB, Yu AP, et al. Persistence and
adherence of medications for chronic overactive
bladder/urinary incontinence in the California Medic-
aid program. Value Health 2005;8:495–505.
17 Boccuzzi SJ, Le TK, Wogen J, et al. Utilization pat-
terns associated with tolterodine immediate release
versus oxybutinin in the management of urinary
incontinence. Value Health 2002;5:274.
18 Chui MA, Williamson T, Arciniega J, et al. Patient
persistency with medications for overactive bladder.
Value Health 2004;7:366.
19 Zhou Z, Barr C, Torigie Y, et al. Persistence of
therapy with drugs for overactive bladder. Value
Health 2001;4:161.
20 Diokno AC. Epidemiology and psychosocial aspects
of incontinence. Urol Clin North Am 1995;22:481–
5.
21 Stewart WF, Van Rooyen JB, Cundiff GW, et al.
Prevalence and burden of overactive bladder in the
United States. World J Urol 2003;20:327–36.
22 Sissins P, Barron RL. Reliability and validity of the
overactive bladder-patient satisfaction with treatment
questionnaire (OAB-PSTQ). Qual Life Res 2005;14:
2032.
23 Barron RL, Sissins P. Development of a patient satis-
faction with treatment questionnaire for overactive
bladder (OAB-PSTQ). Qual Life Res 2005;14:2144.
24 Milsom I, Abrams P, Cardozo L, et al. How wide-
spread are the symptoms of an overactive bladder and
how are they managed? A population-based preva-
lence study. BJU Int 2001;87:760–6.
25 Abrams P, Freeman R, Anderstrom C, et al. Toltero-
dine, a new antimuscarinic agent: as effective but
better tolerated than oxybutynin in patients with an
overactive bladder. Br J Urol 1998;81:801–10.
26 Appell RA. Clinical efﬁcacy and safety of tolterodine
in the treatment of overactive bladder: a pooled analy-
sis. Urology 1997;50:90–6; discussion 97–9.
27 Chapple CR, Rechberger T, Al-Shukri S, et al. Ran-
domized, double-blind placebo- and tolterodine-
controlled trial of the once-daily antimuscarinic agent
solifenacin in patients with symptomatic overactive
bladder. BJU Int 2004;93:303–10.
28 Abrams P, Malone-Lee J, Jacquetin B, et al. Twelve-
month treatment of overactive bladder: efﬁcacy and
tolerability of tolterodine. Drugs Aging 2001;18:551–
60.
29 Appell RA, Abrams P, Drutz HP, et al. Treatment of
overactive bladder: long-term tolerability and efﬁcacy
of tolterodine. World J Urol 2001;19:141–7.
30 Herschorn S, Becker D, Miller E, et al. Impact of a
health education intervention in overactive bladder
patients. Can J Urol 2004;11:2430–7.
31 Day PL. Findings of a three-year retrospective study to
investigate prevalence and incidence of urinary incon-
tinence and overactive bladder in a typical managed
care setting. Pharm Pract Manag Q 2000;20:1–11.
32 MacDiarmid S, Rosenberg M. Overactive bladder in
women: symptom impact and treatment expectations.
Curr Med Res Opin 2005;21:1413–21.
33 Rodriguez LV, Blander DS, Dorey F, et al. Discrep-
ancy in patient and physician perception of patient’s
quality of life related to urinary symptoms. Urology
2003;62:49–53.
732 Campbell et al.
